Indirubin-3'-monoxime promotes autophagic and apoptotic death in JM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells.

@article{Lee2013Indirubin3monoximePA,
  title={Indirubin-3'-monoxime promotes autophagic and apoptotic death in JM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells.},
  author={Ming‐Yang Lee and Yi-Wen Liu and Ming-Ho Chen and Jin-yi Wu and Hsing-Ying Ho and Qwa-Fun Wang and Jing-jing Chuang},
  journal={Oncology reports},
  year={2013},
  volume={29 5},
  pages={
          2072-8
        }
}
Indirubin is the active component of Dang gui Long hui Wan, a traditional Chinese herbal medicine used as therapy for chronic myelogenous leukemia (CML). In clinical studies, indirubin seldom caused major side-effects. However, the functional effect of indirubin on acute lymphoblastic leukemia (ALL) is unclear. Therefore, we investigated the effects of indirubin-3'-monoxime (I3M) on the ALL cell line JM1 and the CML cell line K562 (control). The anti-leukemia effects and mechanisms of I3M were… Expand
Indirubin-3'-monoxime induces paraptosis in MDA-MB-231 breast cancer cells by transmitting Ca2+ from endoplasmic reticulum to mitochondria.
TLDR
I3M induced proteasomal dysfunction-mediated ER stress and subsequently promoted Ca2+ release, which was accumulated in the mitochondria via MCU, thus causing paraptosis in MDA-MB-231 breast cancer cells. Expand
Enhancing effects of indirubin on the arsenic disulfide-induced apoptosis of human diffuse large B-cell lymphoma cells
TLDR
Investigating the indirubin-enhanced effects of arsenic disulfide (As2S2) on the proliferation and apoptosis of diffuse large B-cell lymphoma (DLBCL) cells demonstrated that with regard to antitumor activities, As2 S2 served as the principal drug, whereas indirUBin served asThe adjuvant drug. Expand
Inhibition of Suicidal Erythrocyte Death by Indirubin-3’-Monoxime
TLDR
IDM is a novel inhibitor of suicidal erythrocyte death following ionomycin treatment, t-BHP treatment and energy depletion, and may counteract anemia and impairment of microcirculation, at least in part, by inhibition of Ca2+ entry into ERYthrocytes. Expand
Indirubin‐3'‐oxime suppresses human cholangiocarcinoma through cell‐cycle arrest and apoptosis
TLDR
It is suggested that I3O could suppress tumor growth by regulating the cell cycle and inducing apoptosis, and is a potential therapeutic agent for treating human CCA. Expand
Indirubin exerts anticancer effects on human glioma cells by inducing apoptosis and autophagy
TLDR
Investigation of mechanism of action revealed that Indirubin exerts growth inhibitory effects on the U87 and U118 glioma cells by autophagic and apoptotic cell death and may prove essential in the management ofglioma. Expand
Semi-synthesis of indirubin-3′-oxime from Strobilanthes cusia leaves, its acute and sub-chronic toxicity, in vitro and in vivo antitumor activity in Lewis lung carcinoma bearing mice
Indirubin-3′-oxime (IOX) is known to possess anticancer properties by inhibiting cell proliferation of various human cancer cell lines. In the present study, IOX was prepared directly from anExpand
The Role of Indirubins in Inflammation and Associated Tumorigenesis.
TLDR
This chapter will review the field of indirubin research from its discovery, synthesis, chemical modification, structure-activity relationship, and mechanism of action to molecular targets comprising recent advantages and new findings in the context of inflammation-associated signaling pathways, in particular in tumorigenesis, including NF-κB, STAT3, TGF-ß, and AhR. Expand
Elaborating the Role of Natural Products-Induced Autophagy in Cancer Treatment: Achievements and Artifacts in the State of the Art
TLDR
The tumor suppressive action of natural products-induced autophagy may lead to cell senescence, provoke apoptosis-independent cell death, and complement apoptotic cell death by robust or target-specific mechanisms. Expand
Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases
Indirubin is the active component of Danggui Longhui Wan, a traditional Chinese medicine formulation. The encouraging clinical results from the 1980s obtained in chronic myelocytic leukemia patientsExpand
Deciphering the mechanism of Indirubin and its derivatives in the inhibition of Imatinib resistance using a “drug target prediction-gene microarray analysis-protein network construction” strategy
TLDR
Indirubin and its derivatives may be new drugsthat can combat imatinib resistance through the cytokine-cytokine receptor signalling pathway, the JAK-stat pathway, and the NF-KB signalling pathway. Expand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
5'-nitro-indirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells.
TLDR
5'-NIO inhibits the proliferation of human KB oral carcinoma cells via the cell cycle arrest in G2/M phase and is followed by apoptosis, suggesting the potential value of 5'NIO as a candidate for a therapeutic modality for the treatment of oral cancer. Expand
Indirubin-3-monooxime induced cell cycle arrest and apoptosis in Hep-2 human laryngeal carcinoma cells.
TLDR
It is concluded that indirubin-3-oxime induces cell death and apoptosis in human laryngeal carcinoma cells. Expand
5'-Nitro-indirubinoxime induces G1 cell cycle arrest and apoptosis in salivary gland adenocarcinoma cells through the inhibition of Notch-1 signaling.
TLDR
It is found that 5'-NIO induces cell cycle arrest and apoptosis by down-regulating Notch-1 signaling following the secretion of cytochrome c and the activation of caspase-3 and caspases-7 in SGT cells. Expand
Indirubin, a Chinese anti‐leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL‐60 cells
TLDR
Indirubin augments the neutrophilic differentiation of human myelocytic leukaemia HL‐60 cells through inhibition of CDK2 and activation of PU.1.1, which acts specifically at the stage of promyelocyte differentiation into neutrophils and monocytes. Expand
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
TLDR
The results of this study strongly suggest that inhibition of CDK activity in human tumour cells is a major mechanism by which indirubin derivatives exert their potent antitumour efficacy. Expand
Inhibition of normal lymphocyte proliferation by Indirubin-3′-monoxime: A multifactorial process
TLDR
The inhibition of lymphocyte proliferation by IO indicates that indirubin derivatives may be potent immunosuppressive agents. Expand
A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
TLDR
Results provide a biochemical basis for possible clinical application of PHII-7 alone or in combination with conventional antineoplastic agents in the treatment MDR tumors. Expand
Synthesis of Thia‐Analogous Indirubin N‐Glycosides and their Influence on Melanoma Cell Growth and Apoptosis
TLDR
The first synthesis of thia-analogues of indirubin-Nglycosides and their influence on melanoma cell growth, apoptosis and intracellular signaling is reported. Expand
Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative--Enhancement of both extrinsic and intrinsic apoptosis pathways.
TLDR
Evidence is presented that the recently described indirubin derivative 8-Rha-β enhances melanoma cell sensitivity for death ligands and overcomes resistance to TRAIL and CD95 agonists and combination with kinase inhibitors may help for a breakthrough of TRAIL-mediated strategies in melanoma. Expand
7-Bromoindirubin-3′-oxime induces caspase-independent cell death
TLDR
Although their molecular targets remain to be identified, 7-substituted indirubins may constitute a new class of potential antitumor compounds that would retain their activity in cells refractory to apoptosis. Expand
...
1
2
3
...